RBC Affirms Aerie Pharma (AERI) at 'Outperform'; Positive on Data from Another Rho Kinase Inhibitor

October 18, 2016 7:59 AM EDT
Get Alerts AERI Hot Sheet
Price: $42.50 --0%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AERI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

RBC Capital is out positive on Aerie Pharmaceuticals (Nasdaq: AERI) amid a recent AAO update. The firm has AERI at Outperform with a price target of $55.

Analyst Adnan Butt commented today: Data from another rho kinase inhibitor shows improved efficacy over Avastin when combined in DME patients, which could be an additional opportunity for Rhopressa as well. This also means there could be unrealized value in AERI’s compound library that a potential acquirer may pay for on top of Rhopressa/Roclatan. Furthermore, experts on a glaucoma panel thought Roclatan’s 1.5 mmHg difference in efficacy is clinically meaningful.

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

RBC Capital

Add Your Comment